FDA Partners with Commonwealth Informatics to Build Drug Safety Analysis Platform

February 4, 2016

FDA & Commomwealth Information Partner to Build Platform to Analyze Drug Safety Data

On January 28, 2016, the FDA and Commonwealth Informatics entered into a two-year agreement where they will work together to develop a platform to help the Agency assess drug safety data. The agreement was signed as part of the FDA’s 21st Century Review Initiative, which is a set of standards that was developed in an effort to organize and integrate the drug review process, as well as ensure that all decision makers are heard.

Commonwealth Informatics is a Massachusetts-based analytics company that provides cloud-based products and services to regulators, academic professionals, government agencies, and life sciences companies to advance the way clinical data is analyzed. Prior to engaging with the FDA, Commonwealth created a platform called Commonwealth Clinical Data Analytics (CCDA). CCDA was developed in collaboration with the Army Pharmacovigilance Center and is used to monitor drug side effects experienced by more than 15 million patients.

Commonwealth plans to use CCDA as the foundation for its partnership with the FDA, making enhancements to the platform as necessary “to improve the speed and quality of data reviews and the critical analysis of drug safety data.” Commonwealth will do this with assistance from the FDA, as it will be providing scientific, statistical, and clinical support to help the company make improvements to the platform. By working together, the FDA and Commonwealth ultimately hope to “improve the speed, quality, and transparency of analyzing drug safety data,” allowing regulators to make more informed decisions.

At the project’s outset, Commonwealth will host the program using its internal cloud infrastructure. As the platform progresses it will be integrated with some of the FDA’s custom-developed tools and programs, such as the openFDA platform. As such, Commonwealth eventually plans to turn the platform over to FDA, who will host the program internally at some point in the future.

Are you in the process of developing a new drug? Are you preparing for a pre-IND or EOP2 meeting? Are you developing an IND or NDA for submission to the FDA? We can help. Using our proprietary approach, we have a track record of helping our clients achieve positive outcomes with FDA. To learn more about our services and how we can help you, contact us today.

Agency Alerts General Regulatory

August 28, 2015

FDA Extends Comment Period For Its “Request for Quality Metrics” Draft Guidance

Last month, FDA published a draft guidance titled “Request for Quality Metrics,” which outlined the ways in which it intends to collect and use quality metrics. The guidance states that the data will...

Read the Full Article
Agency Alerts

February 24, 2016

FDA Submissions for Interoperable Medical Devices – Comment Period Extended for Draft Guidance

Additional information on FDA’s recommendations for interoperable medical devices is available in our blog post entitled “A Closer Look at FDA’s Draft Guidance Regarding Premarket Submissions for...

Read the Full Article
Agency Alerts

January 28, 2016

FDA Extends Comment Period for Emerging Medical Device Signals Draft Guidance

On December 31, 2015, FDA released a draft guidance entitled “Public Notification of Emerging Postmarket Medical Device Signals (‘Emerging Signals’),” which stated its plans to take a more aggressive...

Read the Full Article